Abstract
In hepatology, hepatocellular carcinoma (HCC), not outer space, is the final frontier (sorry, Star Trek fans, https://www.youtube.com/watch?v=S6R3MiAv9ac), given its extremely heterogeneous molecular pathogenesis, dismal prognosis and limited treatment options [1]. Treatment of this neoplasm remains a huge unmet need with no major successes imminent, in contrast to the recent transformative progress in HCV antivirals, and the heightened prospects for antifibrotic therapies. Two articles, by Perra et al.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
